Simon Beaven, MD
Internal Medicine · Los Angeles, CANPI 1205018967
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $21,675 of the $23,518 with a category attached, or 92.2%. Alnylam Pharmaceuticals Inc. accounts for 97.7% of it on its own, with 9 other manufacturers making up the rest. 2025 is the largest year on record at $23,124, more than ten times the $164 reported in 2019. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 35 payments — averaging $671.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$23K
- Boston Scientific$136
- Pfizer$130
- Dova Pharmaceuticals$125
- Madrigal Pharmaceuticals$70
- Olympus America Inc.$21
- plus $53 from 4 others
What the payments were for
- Speaking & faculty fees$21,67592%
- Travel & lodging$5312%
- Food & beverage$1,3126%
- Education$10%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 17 | $22,984 |
| Boston Scientific | 5 | $136 |
| Pfizer | 6 | $130 |
| Dova Pharmaceuticals | 1 | $125 |
| Madrigal Pharmaceuticals | 1 | $70 |
| Olympus America Inc. | 1 | $21 |
| Apollo Endosurgery US Inc | 1 | $21 |
| Covidien LP | 1 | $18 |
| AbbVie | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,518 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 13 | $39,291 |
| VemlidyTenofovir Alafenamide | 14 | $18,176 |
| Lactulose | 28 | $984 |
| Spironolactone | 28 | $361 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $305 |
| Pantoprazole Sodium | 15 | $235 |
| Omeprazole | 17 | $227 |
| Furosemide | 30 | $159 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.